Figure 3: CM-272 induces type I IFN response and immunogenic cell death. | Nature Communications

Figure 3: CM-272 induces type I IFN response and immunogenic cell death.

From: Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Figure 3

(a) Enrichment of ISGs published by Schoggins and colleagues31 and Sistigu and colleagues32 in CEMO-1, MV4-11 and OCI-Ly10 cell lines using GSEA. (b) Gene expression of ISGs published by Schoggins JW et al. and Sistigu and colleagues after 48 h of CM-272 treatment in CEMO-1, MV4-11 and OCI-Ly10 cell lines. (c) qRT-PCR validation of ISGs in CEMO-1 and MV4-11 cell lines after 48 h of CM-272 treatment. (d) qChIP-PCR analysis of ISGs in CEMO-1 and MV4-11 treated for 48 h with 250 and 270 nM of CM-272, respectively. (e) Calreticulin exposure determined by FACS analysis of CEMO-1, MV4-11 and OCI-Ly10 cells after 48 h of treatment with GI25 and GI50 of CM-272. (f) HMBG1 secretion determined by ELISA analysis of supernatants of CEMO-1, MV4-11 and OCI-Ly10 cells after 48 h of treatment with GI25 and GI50 of CM-272. Error bars indicate s.d. from three replicates.

Back to article page